title: The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.
abstract: PML is a nuclear protein with growth-suppressive properties originally identified in the context of the PML-retinoic acid receptor alpha (RAR alpha) fusion protein of acute promyelocytic leukemia. PML localizes within distinct nuclear structures, called nuclear bodies, which are disrupted by the expression of PML-RAR alpha. We report that PML colocalizes with the nonphosphorylated fraction of the retinoblastoma protein (pRB) within nuclear bodies and that pRB is delocalized by PML-RAR alpha expression. Both PML and PML-RAR alpha form complexes with the nonphosphorylated form of pRB in vivo, and they interact with the pocket region of pRB. The regions of PML and PML-RAR alpha involved in pRB binding differ; in fact, the B boxes and the C-terminal region of PML, the latter of which is not present in PML-RAR alpha, are essential for the formation of stable complexes with pRB. Functionally, PML abolishes activation of glucocorticoid receptor-regulated transcription by pRB, whereas PML-RAR alpha further increases it. Our results suggest that PML may be part of transcription-regulatory complexes and that the oncogenic potential of the PML-RAR alpha protein may derive from the alteration of PML-regulated transcription.
authors.affiliation: Department of Experimental Oncology, European Institute of Oncology, Milan, Italy. malcalay@ieo.cilea.it
authors.forename: M
authors.initials: M
authors.lastname: Alcalay
authors.forename: L
authors.initials: L
authors.lastname: Tomassoni
authors.forename: E
authors.initials: E
authors.lastname: Colombo
authors.forename: S
authors.initials: S
authors.lastname: Stoldt
authors.forename: F
authors.initials: F
authors.lastname: Grignani
authors.forename: M
authors.initials: M
authors.lastname: Fagioli
authors.forename: L
authors.initials: L
authors.lastname: Szekely
authors.forename: K
authors.initials: K
authors.lastname: Helin
authors.forename: P G
authors.initials: PG
authors.lastname: Pelicci
mesh_terms: D002455:Cell Division; D006801:Humans; D002479:Inclusion Bodies / Q000378:metabolism; D046911:Macromolecular Substances; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D000071156:Promyelocytic Leukemia Protein; D011485:Protein Binding; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins
chemical_list: D046911:Macromolecular Substances; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D000071156:Promyelocytic Leukemia Protein; D011965:Receptors, Glucocorticoid; D016160:Retinoblastoma Protein; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; C070576:PML protein, human